I-Mab is a holding company. Through its subsidiaries, Co. is a clinical stage biopharmaceutical company focuses on the discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs. Co.'s drug pipeline includes: TJ202 (MOR202), a human, monoclonal antibody directed against CD38; TJ107, a recombinant human interleukin-7, which is developed as a T lymphocyte-booster for cancer-related immunotherapy; and TJM2, an internally discovered neutralizing antibody against human granulocyte-macrophage colony-stimulating factor, a cytokine that plays a role in chronic inflammation and destruction in autoimmune diseases such as rheumatoid arthritis. The IMAB stock yearly return is shown above.
The yearly return on the IMAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|